Q-Line Biotech IPO Review: GMP, Price Band, Dates, Allotment & Valuation Analysis

Q-Line Biotech Limited is set to launch its Initial Public Offering (IPO). It is a prominent player in the In-Vitro Diagnostics (IVD) sector.

The public issue will open for subscription on Thursday, May 21, 2026, and close on Monday, May 25, 2026. Through this 100% book-built fresh issue, the company aims to raise approximately ₹214.48 Crores at the price band of ₹326 – ₹343 per equity share.

Track all the latest IPOs at our upcoming IPO section.

Q-Line Biotech specializes in manufacturing and supplying a wide array of IVD products, including clinical chemistry, hematology reagents, and medical equipment.

In this article, you will find Q-Line Biotech IPO GMP today,  price band, and a detailed review with financial analysis and valuations.

Briefs of Q-Line Biotech IPO Details:

• Price Band: ₹326 – ₹343 per equity share
• Face Value: ₹10 per share
• IPO Open / Close Dates: May 21, 2026 – May 25, 2026
• Lot Size: 400 Shares (Note: Retail Minimum Application is 2 Lots / 800 Shares)
• Issue Size: 62,53,200 Equity Shares / ~₹214.48 Crores
• Fresh Issue: 100% Fresh Issue
• Registrar: Purva Sharegistry (India) Pvt. Ltd.
• Listing Exchange: NSE SME

IPO Reservation:

The offering comprises a total issue size of 62,53,200 shares. Excluding 3,13,200 shares reserved for the Market Maker, the net offer to the public is 59,40,000 shares, allocated as follows:

• QIB Portion: Not more than 29,69,200 Equity Shares (Anchor Investors may be allocated up to 17,81,200 Equity Shares from this portion).
• NII (HNI) Portion: Not less than 8,91,600 Equity Shares.
• Retail (RII) Portion: Not less than 20,79,200 Equity Shares.

What Is The Q-Line Biotech IPO GMP Today?

Monitor current trends for upcoming IPOs on our central GMP hub.

 Grey Market Premium (GMP) is completely unofficial and lacks regulation by SEBI, NSE, or BSE. 

What Are The Important Q-Line Biotech IPO Dates & Allotment Schedule?

For investors planning their capital allocation, here is the critical timeline for the issue:

• IPO Open Date: Thursday, May 21, 2026
• IPO Close Date: Monday, May 25, 2026
• Basis of Allotment Date: Tuesday, May 26, 2026
• Refund Initiation Date: Wednesday, May 27, 2026
• Credit of Shares: Wednesday, May 27, 2026
• Listing Date: Friday, May 29, 2026

What Are The Objectives of Q-Line Biotech IPO?

The company proposes to utilize the Net Proceeds from the Fresh Issue towards the following strategic purposes:

1. 1. Working Capital Requirements: A massive ₹93.50 Crores is earmarked for meeting incremental working capital requirements. This is vital to manage the high trade receivable days and support day-to-day operations in the capital-intensive medical device and reagent supply chain.

1. 1. Repayment of Borrowings: ₹90.00 Crores will be utilized to prepay or repay outstanding borrowings, which will directly reduce the company’s interest burden and improve the debt-to-equity ratio.

1. 1. General Corporate Purposes: The remaining funds (capped at 15% of gross proceeds or ₹10 Crores) will cover ongoing operational contingencies and brand-building exercises.

How is The Financial Performance of Q-Line Biotech?

The following table summarizes the financial performance of the company based on restated consolidated financial statements.

(Figures in ₹ Crores)

                                                     Source: RHP

Financial Analysis & Observations:

Total Income:

The company demonstrated exceptional revenue growth, leaping from ₹184.81 Crores in FY23 to ₹322.58 Crores in FY25.

This robust expansion is primarily driven by the increasing demand for IVD diagnostics and the successful rollout of new reagent formulations in domestic markets.

Profit After Tax (PAT):

While PAT dipped slightly to ₹28.13 Crores in FY25 (due to losses from an associate company’s exit), it rebounded aggressively to ₹38.69 Crores in just the first nine months of FY26.

This highlights strong underlying operational profitability and recovery.

EBITDA:

Operational efficiency is improving markedly. EBITDA more than doubled from ₹32.98 Crores in FY23 to ₹71.32 Crores in FY25.

The EBITDA margins expanded from 18.05% to 22.73% during the same period, showcasing better pricing power and cost absorption as the company scales.

Total Borrowing:

To fund its heavy working capital needs, particularly due to extended credit terms offered to hospitals (160 debtor days by Dec 2025), total borrowings surged to ₹243.85 Crores.

The IPO proceeds allocated for debt repayment (₹90 Crores) are a crucial step to manage this leverage.

Assets:

The asset base expanded massively to ₹561.34 Crores by December 2025. This growth is heavily weighted towards current assets like trade receivables, underscoring the working-capital-intensive nature of the B2B medical supply business.

What Are The P/E Ratio and Peer Comparison?

Based on its Fiscal Year 2026 earnings per share (EPS) of ₹28.63, the IPO is priced at a Price-to-Earnings (P/E) multiple of approximately 11.98x at the upper end of the price band (₹343).

P/E Ratio = ₹343(Price) / ₹28.63 (Earnings Per Share)

P/E Ratio ≈ 11.98x

Peer Comparison:

According to the Red Herring Prospectus (RHP), there are no listed companies in India that are engaged in a business line strictly similar to that of Q-Line Biotech Limited (specifically the integrated manufacturing and trading of IVD reagents and machinery at this scale).

Therefore, a direct peer comparison table is not available.

Analysis:

Q-Line Biotech is entering the market at a P/E multiple of approximately 11.98x based on its FY25 EPS. In the absence of direct listed peers, investors must evaluate this valuation against the company’s internal growth metrics.

Given the robust Return on Net Worth (RoNW) of 23.74% in FY25 and the aggressive top-line growth (31% CAGR), the valuation appears reasonable.

However, the market will weigh this attractive pricing against the company’s high debt levels and recent negative operating cash flows.

What is The Industry Outlook of Q-Line Biotech?

Growth Potential:

The Indian In-Vitro Diagnostics (IVD) market is experiencing rapid growth, driven by increasing awareness of preventive healthcare, an aging population, and government initiatives aiming to expand healthcare infrastructure in Tier-2 and Tier-3 cities. 

Market Trends:

There is a distinct shift towards automated diagnostic systems and localized manufacturing of reagents to reduce import dependency. Q-Line’s focus on R&D and reverse engineering positions it well to capture this import substitution trend.

What Are The Strengths and Risks of Q-Line Biotech IPO?

Strengths:

• • Robust Revenue Growth: The company has delivered a solid 31% CAGR in revenue from FY23 to FY25, highlighting strong market acceptance of its diagnostic products.

• • Improving Margins: The expansion of EBITDA margins (up to 27.64% in the recent 9-month period) demonstrates excellent operational leverage and efficiency.

• • Deleveraging Plan: The strategic use of ₹90 Crores from the IPO to repay debt will structurally improve net margins post-listing.

Risks:

• • Working Capital & Cash Flow: The business has an extremely high debtor days cycle (160 days in Dec 2025), leading to consistently negative operating cash flows (-₹33.11 Crores in 9M FY26).

• • Extreme Concentration: The top 2 distributors account for over 72% of sales, with a single group entity (POCT Services) contributing over 60%. Loss of this distributor would be devastating.

• • Regulatory & Tax Issues: Recent income tax search and seizure operations against the promoters pose a significant reputational and potential financial risk.

Key Considerations for Investors

Investors should note the Minimum Investment structure.

• • Minimum Application: The lot size is 400 Shares. Based on the data provided, the minimum application for Retail Individual Investors is 2 Lots (800 Shares), amounting to ₹2,74,400. Note: This investment amount exceeds the typical ₹2 Lakh retail limit, which implies this category effectively targets Small-HNI investors.

• • Valuation vs. Risk: At ~12x P/E, the pricing seems to discount the risks associated with the negative cash flows and tax litigation overhang.

• • Sector Play: This is a strong play on the Indian healthcare diagnostics sector, provided the company can manage its working capital cycle effectively.

Key Takeaways

• IPO Price: ₹343 per share (Upper Band).
• Min Investment: ₹2,74,400 (800 Shares).
• Financials: Revenue ₹322 Cr (FY25);
• Allotment: May 26, 2026
• Listing: NSE SME platform on May 29, 2026.

Important Links:

1. Check IPO allotment Status
2. Daywise subscription details of IPOs
3. IPO research and data analytics

FAQs on Q-Line Biotech IPO

What is Q-Line Biotech IPO GMP today?

The GMP is a dynamic market sentiment indicator. Check at our dedicated GMP section for the latest updates.

What is Q-Line Biotech IPO price band?

The price band is fixed at ₹326 to ₹343 per equity share.

What is Q-Line Biotech IPO allotment date?

The allotment status is expected to be finalized on Tuesday, May 26, 2026.

How to check Q-Line Biotech IPO allotment status?

Investors can check the status on the website of Purva Sharegistry (India) Pvt. Ltd. (the Registrar) or via the NSE IPO allotment portal.

What is Q-Line Biotech IPO listing date?

The shares are tentatively scheduled to list on Friday, May 29, 2026.

Investment Perspective on Q-Line Biotech IPO

Q-Line Biotech offers a high-growth opportunity in the vital healthcare diagnostics sector. While the financial performance and valuation multiple are highly attractive, the severe client concentration, negative operating cash flows, and recent tax investigations are critical risk factors that conservative investors must weigh carefully.

Disclaimer:  This article is strictly for educational purposes. Please consult a SEBI-registered investment advisor before making any investment decisions.